Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
Articles, Neurobiology of Disease

Changed Histone Acetylation Patterns in Normal-Appearing White Matter and Early Multiple Sclerosis Lesions

Xiomara Pedre, Fabrizio Mastronardi, Wolfgang Bruck, Gerardo López-Rodas, Tanja Kuhlmann and Patrizia Casaccia
Journal of Neuroscience 2 March 2011, 31 (9) 3435-3445; DOI: https://doi.org/10.1523/JNEUROSCI.4507-10.2011
Xiomara Pedre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrizio Mastronardi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang Bruck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerardo López-Rodas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanja Kuhlmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrizia Casaccia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Histone H3 acetylation in the frontal cortex of MS and normal brains. A, Immunocytochemical analysis of histone H3 acetylation of white matter in the frontal lobes of control subjects, without neurological disease. B, Double stainings were performed with antibodies specific for acetyl-H3 (AcH3) (black) and either NogoA (red) to identify oligodendrocytes, KiM1P to identify microglia, and GFAP to label astrocytes. Examples of an AcH3-negative microglial cell, an AcH3-positive astrocyte, and AcH3-positive (arrows) and -negative oligodendrocytes are shown. C, Quantification of nuclei immunoreactive for acetylated histone H3 in the white matter of the frontal lobes of young (21–30 years) and old (71–80 years) male (squares) and female (circles) subjects. D, Quantification of total acetyl-H3+ nuclei in the frontal cortex of non-neurological (CTRL) and MS patients demonstrating a significantly increased percentage of acetyl-H3+ nuclei in chronic MS brains (Mann–Whitney test; *p < 0.05). E, Scatterplot of the amount of acetylated H3 protein levels isolated from CTRL and MS patients. Proteins were isolated from frozen frontal lobes perilesional and NAWM of control and MS patients and processed by slot blot using antibodies against acetyl-H3 and total H3 to measure global levels of acetylation on the tail of histone H3 (two-tailed t test; *p < 0.05; **p < 0.01).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Dysregulated expression of downstream effectors of developmental myelination pathway in the NAWM of a subset of patients with chronic MS. Quantitative real-time PCR analysis of transcripts involved in the Wnt (i.e., TCF7L2), BMP4 (i.e., ID2), and Notch (i.e., JAG1) pathway. The levels of the neural stem cell marker SOX2, myelin genes (i.e., MAL, MOG, and MBP), and tubulin α (TUBA) were also determined. The RNA was isolated from NAWM samples from the frontal lobes of patients with chronic MS and non-neurological controls. The values of the qRT-PCR of the target genes were referred to those of transcripts for the ribosomal protein 60S subunit. Note that the same patients with high levels of TCF7L2 were also the ones with high levels of ID2 and SOX2. Each patient is identified by the same color in all diagrams (two-tailed t test with Welch's correction; *p < 0.05; **p < 0.01).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Correlation between TCF7L2 and MOG transcripts levels. A, Linear regression curve addressing the relations between TCF7L2 and MOG transcript levels in control and MS patients. Note the presence of two subgroups of female patterns, one displaying a linear positive correlation between the two variables and one with a negative correlation. No correlation was detected in males. B, Correlation plot between TCF7L2 transcripts levels and disease duration in MS patients. Linear regression of the female but not male transcript levels is significantly different from zero; p < 0.05.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Selective changes of histone deacetylase transcript levels in the frontal lobes of chronic MS brains. Quantitative RT-PCR of RNA isolated from white matter samples in the frontal cortex of non-neurological controls and MS patients to detect transcript levels of histone deacetylases. The relative levels of expression were first normalized to the transcript levels of the ribosomal protein of the 60S subunit and then expressed as fold changes over the average values calculated in male or female non-neurological controls. The individual values are shown as triangles for females and circles for males. The median value of the ranking distribution is shown by a line.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Increased levels of histone acetyltransferase transcripts in the frontal lobes of a subset of patients with chronic MS. Quantitative RT-PCR of RNA isolated from white matter samples in the frontal cortex of non-neurological controls and MS patients to detect transcript levels of distinct classes of histone acetyltransferases, including MYST3, MYST4, and TIP60 (A), and P300, PCAF, GCN5, and CBP (B). The relative levels of expression were normalized to the levels of 60S RNA protein transcripts and then expressed as fold changes over the average values calculated in male or female non-neurological controls. The individual values are shown as triangles for females and circles for males. The median value of the ranking distribution is shown by a line. Note the increased levels of P300 and CBP in female MS patients compared with controls (two-tailed t test with Welch's correction; *p < 0.05; **p < 0.01). C, Correlation between P300 or CBP levels and TCF7L2. Linear regression of female but not male MS patients is significantly different from zero; p < 0.05.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Increased histone H3 acetylation in the region corresponding to TCF7L2, and TUBA, in chromatin samples from MS patients. A, B, TCF7L2 and TUBA gene loci from UCSC genome browser. The regions amplified in the ChIP experiment are shown as black boxes. C, D, After isolation of chromatin from the NAWM of the frontal lobes of patients with chronic MS and non-neurological controls, samples were immunoprecipitated with antibodies against acetyl-H3 and then assayed using quantitative PCR. The values are referred as percentage of enrichment of the signal in the immunoprecipitated samples relative to nonprecipitated chromatin (i.e., input control). Note the more prominent acetylation in female MS patients compared with controls detected at the TCF7L2 locus (C), but not at the constitutively expressed TUBA locus (D) patients (two-tailed t test with Welch's correction; *p < 0.05; **p < 0.01). Error bars indicate SEM.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Reduced histone H3 acetylation in oligodendrocyte lineage cells in early MS lesions. A, The percentage of acetyl-H3+ oligodendrocyte lineage cells is significantly reduced in actively demyelinating, demyelinated, and remyelinating lesion areas compared with the periplaque white matter (ANOVA with Bonferroni's correction; *p < 0.05; **p < 0.01). B, C, Double staining for acetyl-H3 (black) and NogoA (red) in PPWM (B) and a remyelinating lesion area (C) are shown; both pictures are taken from the same patient. In the PPWM, numerous acetyl-H3+ NogoA+ oligodendrocytes are found (arrows), whereas in remyelinating areas numerous acetyl-H3− NogoA+ oligodendrocytes (arrowheads) are observed. PPWM, Periplaque white matter; active, actively demyelinating; DM, demyelinated; RM, remyelinating.

Tables

  • Figures
    • View popup
    Table 1.

    Summary of all the MS and non-neurological control samples used for qPCR and ChIP

    Patient IDAgeDisease durationDiagnosisSexPostmortem interval (h)Additional diagnosisExperiment
    MS15121MSF6.5MSqPCR
    MS25132MSF9CPqPCR
    MS36433MSF17.3SPqPCR
    MS46139MSF38SP, CxCqPCR
    MS56426MSF9SPqPCR
    MS65024MSF15SPqPCR
    MS75120MSF19.5SPqPCR
    MS86117MSF22.8PPqPCRChIP
    MS97411MSF9.5PPqPCRChIP
    MS107217MSF40.1SP, BnCqPCR
    MS117529MSF13.8CPqPCR
    MS126318MSF15MSqPCR
    MS137611MSM25SP, ASqPCR
    MS14604MSM17MSqPCR
    MS155914MSM23MSqPCR
    MS166020MSM9MSqPCR
    MS175912MSM15PPqPCR
    MS186523MSM29.4CP, Mel, CnCqPCR
    MS195425MSM16.9CPqPCR
    MS207541MSM12.9SP, PtCqPCRChIP
    MS217139MSM31.7SPqPCR
    MS2269?MSM12.5CP, LgCqPCR
    MS236417MSM12.5CP, COPDqPCRChIP
    N190N/ANF11.8CnCqPCR
    N276N/ANF9CHDqPCR
    N3726NF19.5BrCqPCR
    N4722NF20.1BrCqPCR
    N5794NF14CHDqPCRChIP
    N6731NF12COPDqPCRChIP
    N781N/ANF11.3AS, BrCqPCR
    N8809NM11RnCqPCR
    N9681NM10.5LgC, ischemiaqPCR
    N10757NM11.5PtCqPCRChIP
    N11661NM13.1LxCqPCR
    N127111NM11.5COPDqPCRChIP
    N136416NM17.5LymphomaqPCR
    N1454N/ANM19CHD, ASqPCR
    N1552N/ANM16LgCqPCR
    N16582NM9CnCqPCR
    N1774N/ANM13.6LgCqPCR
    N1881N/ANM14LymphomaqPCR
    N19533NM15MelqPCR
    N20904NM17.8COPD
    • Abbreviations: COPD, Chronic obstructive pulmonary disease; AS, atherosclerosis; CHD, coronary heart disease; Mel, melanoma; CnC, colon cancer; LgC, lung cancer; CvC, cervix cancer; PtC, prostate cancer; BnC, bone cancer; RnC, renal cancer; BrC, breast cancer; LxC, larynx cancer.

    • View popup
    Table 2.

    Summary of all the MS and non-neurological control samples used for immunohistochemistry (IHC)

    Patient IDAgeDisease durationDiagnosisSexAdditional diagnosisExperiment
    MS245715 yearsMSMPPIHC
    MS255941 yearsMSF?IHC
    MS266634 yearsMSMSPIHC
    MS27599 yearsMSFPPIHC
    MS285712 yearsMSMSPIHC
    MS295916 yearsMSFSPIHC
    MS3022?N/AFIHC
    MS316519 dN/AMIHC
    MS323258 dN/AMIHC
    MS336392 dN/AFIHC
    MS3464?N/AMIHC
    MS3533?N/AFIHC
    MS3643?N/AFIHC
    MS3737?N/AFIHC
    MS382831 dN/AMIHC
    MS3928?N/AFIHC
    MS404545 dN/AFIHC
    MS4154?N/AFIHC
    MS4254?N/AFIHC
    MS4320?N/AFIHC
    MS4446?N/AFIHC
    MS4549?N/AMIHC
    MS4642?N/AFIHC
    MS4722?N/AFIHC
    N2123N/ANFIHC
    N2224N/ANFIHC
    N2327N/ANFIHC
    N2428N/ANFIHC
    N2523N/ANFIHC
    N2673N/ANFIHC
    N2777N/ANFIHC
    N2878N/ANFIHC
    N2975N/ANFIHC
    N3030N/ANMIHC
    N3123N/ANMIHC
    N3227N/ANMIHC
    N3323N/ANMIHC
    N3478N/ANMIHC
    N3571N/ANMIHC
    N3671N/ANMIHC
    N3771–80N/ANFIHC
    N3871–80N/ANMIHC
    N3971–80N/ANMIHC
    N4071–80N/ANMIHC
    N4171–80N/ANMIHC
    N4271–80N/ANMIHC
    N4371–80N/ANFIHC
    N4471–80N/ANFIHC
    N4571–80N/ANFIHC
    N4671–80N/ANFIHC
    N4771–80N/ANFIHC
    N4871–80N/ANFIHC
    N4954N/ANMIHC
    N5059N/ANMIHC
    N5154N/ANMIHC
    N5255N/ANMIHC
    N5357N/ANMIHC
    N5454N/ANMIHC
    N5553N/ANMIHC
    N5662N/ANMIHC
    N5763N/ANMIHC
    N5861N/ANMIHC
    N5965N/ANMIHC
    N6057N/ANFIHC
    N6159N/ANFIHC
    N6257N/ANFIHC
    N6352N/ANFIHC
    N6456N/ANFIHC
    N6567N/ANFIHC
    N6668N/ANFIHC
    N6768N/ANFIHC
    N6868N/ANFIHC
    N6966N/ANFIHC
    • View popup
    Table 3.

    Primers used for qPCR

    GeneApproved symbolSequence senseSequence antisenseGene accession no.
    Myst3KAT6ACAAGGCTGCCCAAATTGTATATCTCATTGGCAGGAGGATGNM_006766
    Myst4KAT6BCCAGAAATCTCCACGGAAAAGTTGTGGGATGGCTCTTCATNM_012330
    TIP60KAT5GGCTGAGGACAGCTCAAAAACCGGATCCCTTCTCACTGTANM_006388
    GCN5KAT2AGTTATGGGACCCACCTGATGCGGCGTAGGTGAGGAAGTAGNM_021078
    PCAFKAT2BCCAGCAAAAGAAAGGCAAACATCATTGGGAGATCGCAGTCNM_003884
    CBPKAT3AGCCACGTCCCTTAGTAACCACCCCAAGTGTCCCTGATCTANM_004380
    ELP3KAT9GATTGGGGTGCAGAGTGTTTATCTTTGGCCAGGTGAAATGNM_018091
    P300KAT3BCGCTTTGTCTACACCTGCAATGCTGGTTGTTGCTCTCATCNM_001429
    HDAC1HDAC1GATCTGCTCCTCTGACAAACGAACCCTCTCCCTCCTCTTCAGAANM_004964
    HDAC2HDAC2TGGAGGAGGTGGCTACACAATAATCTCACAATCAAGGGCAACTGU31814
    HDAC3HDAC3TCTACCTCACTGACCGGGTCATACCTGTGCCAGGGAAGAAGTAANM_003883
    HDAC8HDAC8GGATCCCATGTGCTCCTTTAATAGCCTCCTCCTCCCAAAANM_018486
    HDAC11HDAC11GAGCTGGCCCTTCCTCTACTCTATGGGCTGGTGACTTCGTNM_024827
    TCF7L2TCF7L2TGGTGCGGCCCTTGCAGATGTCAAGCCCGAACAGTGCCCGNM_030756
    TCF4TCF4CGAAATCTTCGGAGGACAAGCTTCTCACGCTCTGCCTTCTNM_003199
    JAG1JAG1AAGGGGTGCGGTATATTTCCTCCCGTGAAGCCTTTGTTACNM_000214
    ID2ID2GACAGCAAAGCACTGTGTGGTTCAACCATTTCACAAGGAGGNM_002166
    SOX2SOX2AACCCCAAGATGCACAACTCGCTTAGCCTCGTCGATGAACNM_003106
    MALMALGCCGTGGTGTTCTCCTACATACACCATCTGGGTTTTCAGCNM_002371
    MOGMOGTCACCTGCTTCTTCCGAGATGAGGAGAACCAGCACTCCAGNM_001008228
    MBPMBPTCACAAGGGATTCAAGGGAGTAGGTAACAGGGGCAAGTGGNM_001025081
    • View popup
    Table 4.

    Histological changes in normal appearing white matter from MS patients

    AutopsyKiM1P (cells/mm2)GFAP (cells/mm2)Fiber gliosisAPP (spheroids/mm2)
    MS13375.7+2
    34.787.5+0
    MS22972.5+0
    MS369.3115.4+ND
    MS541.141.1−2.56
    14461+0
    MS659.682.5+1.28
    MS783.296+2.24
    • APP, Amyloid precursor protein.

Back to top

In this issue

The Journal of Neuroscience: 31 (9)
Journal of Neuroscience
Vol. 31, Issue 9
2 Mar 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Changed Histone Acetylation Patterns in Normal-Appearing White Matter and Early Multiple Sclerosis Lesions
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Changed Histone Acetylation Patterns in Normal-Appearing White Matter and Early Multiple Sclerosis Lesions
Xiomara Pedre, Fabrizio Mastronardi, Wolfgang Bruck, Gerardo López-Rodas, Tanja Kuhlmann, Patrizia Casaccia
Journal of Neuroscience 2 March 2011, 31 (9) 3435-3445; DOI: 10.1523/JNEUROSCI.4507-10.2011

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Changed Histone Acetylation Patterns in Normal-Appearing White Matter and Early Multiple Sclerosis Lesions
Xiomara Pedre, Fabrizio Mastronardi, Wolfgang Bruck, Gerardo López-Rodas, Tanja Kuhlmann, Patrizia Casaccia
Journal of Neuroscience 2 March 2011, 31 (9) 3435-3445; DOI: 10.1523/JNEUROSCI.4507-10.2011
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Articles

  • Choice Behavior Guided by Learned, But Not Innate, Taste Aversion Recruits the Orbitofrontal Cortex
  • Maturation of Spontaneous Firing Properties after Hearing Onset in Rat Auditory Nerve Fibers: Spontaneous Rates, Refractoriness, and Interfiber Correlations
  • Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration
Show more Articles

Neurobiology of Disease

  • Altered Development of Amygdala-Connected Brain Regions in Males and Females with Autism
  • Disruption of Endosomal Sorting in Schwann Cells Leads to Defective Myelination and Endosomal Abnormalities Observed in Charcot-Marie-Tooth Disease
  • A Computational Probe into the Behavioral and Neural Markers of Atypical Facial Emotion Processing in Autism
Show more Neurobiology of Disease
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
(JNeurosci logo)
(SfN logo)

Copyright © 2022 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.